ORIENT BIO Inc.

KSE 002630.KS

ORIENT BIO Inc. Net Income Margin for the year ending March 31, 2024: 45.96%

ORIENT BIO Inc. Net Income Margin is 45.96% for the year ending March 31, 2024, a 206.61% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

ORIENT BIO Inc. Net Income Margin for the year ending March 31, 2023 was -43.11%, a -133.12% change year over year.
ORIENT BIO Inc. Net Income Margin for the year ending March 31, 2022 was 130.15%, a 533.06% change year over year.
ORIENT BIO Inc. Net Income Margin for the year ending March 31, 2021 was -30.05%, a -4.13% change year over year.
ORIENT BIO Inc. Net Income Margin for the year ending March 31, 2020 was -28.86%, a 55.06% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

KSE: 002630.KS

ORIENT BIO Inc.

CEO	Mr. Jae-Jin Chang
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	322, Galmachi-ro
Employees	125
Sector	Health Care
Industries Biotechnology

Description

ORIENT BIO Inc. operates in the bio-industry in South Korea. The company produces laboratory animals. In addition, it offers various equipment for research environment. The company was formerly known as Orient Co., Ltd. and changed its name to ORIENT BIO Inc. in 2005. ORIENT BIO Inc. was founded in 1959 and is based in Seongnam, South Korea.

Key trends

Past 5 years